Clinical trials: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, open to volunteers
- Condition Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Status Open to volunteers
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05691465
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE
- Where
- 13 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Trial name
- NCT07179783
- Testing
- Sacituzumab Tirumotecan, Tagitanlimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Second Hospital